Charles River is pleased to announce that our 2014 Research Models and Services catalog is now available electronically.
We have recently received approval to move forward with the expansion of our existing Avian Vaccine Services laboratory manufacturing site to further meet expanding customer demand. The new expanded facility’s ground breaking is imminent.
Interstitial pulmonary fibrosis (IPF) is a severe lung disease with a high mortality rate and with few treatment options. Using a rat model, we have recently demonstrated that bleomycin dosing frequency can be used to modulate the extent of inflammation and fibrosis.
In order to provide a more translational readout from preclinical disease models of MS, we have validated single-photon emission computed tomography (SPECT/CT) imaging for non-invasive longitudinal quantification of neuroinflammation in in vivo preclinical MS rat models.
Charles River is pleased to announce that it has acquired BRASS Pte Ltd (“BRASS”). Building on the partnership established with BRASS in 1997, Charles River aims to accelerate the growth of its portfolio of products and services in Asia by providing clients with state-of-the-art microbial detection and identification for manufacturing in the biopharmaceutical, medical device and life sciences industries.
The Golden Syrian hamster is a well-established species for the study of lipoprotein profiles. It translates to human outcomes because the species carries the cholesteryl ester transfer protein (CETP).
In addition to expanded production capacity for New Zealand White rabbits, we can also provide diet acclimation options to meet your study goals.
We are pleased to announce the relocation of our European endotoxin and microbial detection services to a redesigned, larger facility in Ecully, France and the opening of a brand new facility in Seoul, South Korea.
Intranasal dosing has been used successfully in several toxicology studies in support of clinical trials ranging from acute to chronic. Recently, we have significantly increased the total volume of test items that can be administered via this route.
We are pleased to welcome Dr. Wendell Davis, former Director and Head of the Comparative Pathology and Discovery Toxicology at Biogen Idec, and Dr. Matthew Smith, former veterinary pathologist at Bristol-Myers Squibb, to Charles River. Their collective experience and knowledge of the industry adds significant value to our pathology team.